GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

WARREN, N.J., June 29, 2021 /PRNewswire/ -- GlaxoSmithKline (LSE: GSK) (NYSE: GSK) – Get ready for a red hot American summer!

TUMS® Fuels the Autoburn, a Road Trip to America's Spiciest Destinations, with Hot Food Expert Sean Evans

Churchill Capital Corp IV

Equinor

Home Depot

Microsoft

PayPal

Unilever

While sustainable initiatives sound like a strategy for non-profit organizations, shifting demographics bode well for ESG stocks. The post The 7 Best ESG Stocks to Buy for the Biggest (Socially Responsible) Gains appeared first on InvestorPlace.

The 7 Best ESG Stocks to Buy for the Biggest (Socially Responsible) Gains

Goldman Sachs and Citi are working with GlaxoSmithKline on new listing for a spinoff of its consumer unit, Bloomberg writes. The companies will also help with Glaxo's defense against the possibility of an activist campaign from Elliot Investment Management, which is helmed by billionaire Paul Singer.

GlaxoSmithKline Plans Spinoff Of Consumer Healthcare Unit

GlaxoSmithKline Plc has hired two banks to help advise it on listing its consumer unit next year and on defense against a potential activist campaign from Elliott Investment Management, Bloomberg News reported https://www.bloomberg.com/news/articles/2021-06-25/glaxosmithkline-said-to-tap-goldman-citi-for-spinoff?sref=SCAzRb9t on Friday, citing people familiar with the matter.

GlaxoSmithKline taps Goldman, Citi to advise on consumer unit spinoff - Bloomberg News

GlaxoSmithKline PLC (LON:GSK) seemed to have quelled market concerns after its capital markets day on Wednesday but the hard work is yet to start. Chief executive Emma Walmsley presented her new strategy in what was seen as a 'make it or break it' event for her career, including new growth targets as the pharma giant spins off its consumer healthcare arm next year.

GlaxoSmithKline quells market concerns for now but hard work yet to start

The highly-ranked pharma team at Deutsche Bank has upgraded its call on the stock in GlaxoSmithKline PLC (LON:GSK) after a capital markets day event at which management avoided “any of the several obvious potential banana skins”. The investment bank moved to ‘hold' from ‘sell', nudging up its share price target 3% higher to 1,350p, which it said was a 20% sector discount, “but broadly in-line with relevant large peers”.

GlaxoSmithKline: Did CEO's revamp plan pass City muster? One leading bank has its say

On Wednesday, British multinational pharmaceutical giant GlaxoSmithKline PLC ( GSK , Financial) revealed a sweeping strategic transformation plan aimed towards growing the company's profits and performance over the next decade, improving its pipeline and unlocking value for shareholders.

GlaxoSmithKline: Unlocking Value and Growth With Transformation Plan

The shares of London-based GlaxoSmithKline PLC (NYSE:GSK) are up 3.5% to trade at $40.45 at last check, after the global healthcare company announced plans to spin off its consumer health business.

Pharma Stock Bounces on Spin-Off Plans

Halozyme Therapeutics

Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV

Halozyme (HALO) Inks Collaboration Deal With Glaxo's HIV Unit

GlaxoSmithKline plc (LON: GSK) said on Wednesday its consumer healthcare business will be spun off into a separately listed company. The demerger that was originally announced in December 2018 will eventually result in an $11 billion payment for GSK.

GlaxoSmithKline to spin-off its consumer healthcare business

Britain's GSK set out detailed plans on Wednesday to turn its consumer healthcare arm into a separately listed company, in a move that will bolster the finances of the remaining business to help fund drug development and deals.

Factbox: How GSK plans to fire-up its cash balance post split

CEO Emma Walmsley, facing the possibility of a shareholder revolt, wants to boost profits at the pharmaceutical giant by 10% each year until 2026.

GSK unveils ambitious growth targets after pressure from activist fund Elliott. But is this enough?

British pharmaceutical giant GlaxoSmithKline faces a crunch meeting with investors after announcing a new strategy for the next decade.

GSK chief vows 'step change in growth' as consumer business is split off

GSK set out plans on Wednesday to turn its consumer healthcare business into a separately listed company, aiming to strengthen drug development at its pharmaceuticals business with an 8 billion pound ($11 billion) windfall.

Reaction to GSK's plan to spin off its consumer healthcare business

GlaxoSmithKline PLC (LON:GSK) was on the rise on Wednesday after Emma Walmsley presented the new strategy ahead of an investors update scheduled for the afternoon. The FTSE 100 pharma giant is targeting annual growth of 5% and 10% for sales and adjusted operating profit respectively from 2021 to 2026.

GlaxoSmithKline on the rise after Emma Walmsley unveils new plans

Britain's GSK on Wednesday unveiled a detailed plan to spin off its consumer healthcare venture with Pfizer into a separate company by the middle of next year, as the pharmaceutical giant sharpens its focus on prescription medicines and vaccines.

GSK sets out plans for listing of consumer products venture

11.15am: About to start GlaxoSmithKline PLC (LON:GSK) is due to update investors on its plans for the future. Chief executive Emma Walmsley will focus on the drugs pipeline, details on the biopharma business demerger, earnings projections, updates on COVID-19 projects and dividend cuts.

GlaxoSmithKline Investor Update: what to expect in today's event

Investors should be prepared for the stock to get slammed if GlaxoSmithKline moves to cut its dividend, the "Mad Money" host said.

GlaxoSmithKline investor meeting could set up a buyable dip, Jim Cramer says

The event comes amid a push by the activist hedge fund Elliott Management, which is said to have questioned whether CEO Emma Walmsley should stay on after a spinoff.

Glaxo Will Face Investors Wednesday. Here's What to Know.

Vir Biotechnology

Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make better HIV medicines.

Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death

Wednesday is likely to see all eyes on GlaxoSmithKline as the firm kicks off its eagerly anticipated investor day at the mid-point of the week. Meanwhile, final results from housebuilder Berkeley will provide some more action in the diary, with flash PMIs from the US and the UK providing some macro flavour.

Crunch time for GSK on Wednesday; Berkeley to report on London housing exodus

Crunch time for GSK on Wednesday with Berkeley and PMI readings bringing up the rear

Pfizer

GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme Therapeutics Inc (NASDAQ: HALO) to gain access to Halozyme's Enhanze drug delivery technology for use against four HIV targets. ViiV Healthcare will pay $40 million upfront and up to $175 million in milestones, as well as mid-single-digit royalties on future sales.

GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal

While inflation is the flavour of the day, deflation is a non-negligible risk too in a more normalised environment.

GlaxoSmithKline: Gem In Consumer Healthcare, Deflation Resistant, Keep Watch

LONDON and SAN DIEGO, June 22, 2021 /PRNewswire/ -- ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc ("GSK"), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives exclusive access to Halozyme's ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV.  Under the terms of the agreement, ViiV Healthcare will make an upfront payment of $40 million to Halozyme for the exclusive license to four HIV small and large molecule targets and is obligated to make potential future payments of up to $175 million in development and commercial milestones per target, subject to achievement of specified development and commercial milestones, including certain specified sales milestones.

ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of "ultra-long-acting" medicines for HIV

News for GlaxoSmithKline Stock (GSK)